United Therapeutics Corporation (UTHR)

United Therapeutics Revenue by Segment

Period Ending	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Tyvaso	1.87B	1.88B	1.83B	1.79B	1.71B	1.62B	1.56B	1.45B
Tyvaso Growth	9.05%	15.91%	17.66%	23.39%	25.33%	31.34%	38.18%	36.87%
Remodulin	515.20M	526.80M	533.30M	535.70M	548.30M	538.10M	518.70M	521.50M
Remodulin Growth	-6.04%	-2.10%	2.81%	2.72%	9.35%	8.75%	3.29%	7.50%
Orenitram	511.80M	496.90M	483.50M	465.60M	448.80M	434.30M	410.60M	389.40M
Orenitram Growth	14.04%	14.41%	17.75%	19.57%	18.92%	20.84%	16.95%	12.35%
Unituxin	222.20M	226.80M	232.00M	245.20M	238.50M	238.70M	225.40M	215.60M
Unituxin Growth	-6.83%	-4.99%	2.93%	13.73%	14.55%	20.01%	24.26%	22.36%
Adcirca	26.90M	30.00M	26.90M	24.20M	23.40M	23.80M	25.90M	26.20M
Adcirca Growth	14.96%	26.05%	3.86%	-7.63%	-16.43%	-17.65%	-20.31%	-27.02%
Other	24.30M	24.00M	22.90M	21.50M	20.90M	22.10M	20.50M	16.90M
Other Growth	16.27%	8.60%	11.71%	27.22%	74.17%	166.27%	150.00%	168.25%

Revenue by Geography

Period Ending	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
United States	3.03B	3.04B	2.99B	2.93B	2.85B	2.74B	2.62B	2.49B
United States Growth	6.45%	10.85%	14.12%	17.90%	19.96%	24.41%	25.96%	24.63%
International	138.20M	145.70M	138.50M	145.40M	146.30M	137.70M	136.30M	129.50M
International Growth	-5.54%	5.81%	1.61%	12.28%	17.70%	9.90%	9.65%	12.32%

Source: Business metrics provided by TipRanks and sourced from official company press releases and documents.